News coverage about ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ProShares UltraShort Nasdaq Biotech earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.9753276174474 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of NASDAQ BIS traded up $0.27 during midday trading on Friday, hitting $21.24. The company’s stock had a trading volume of 59,292 shares, compared to its average volume of 80,858. ProShares UltraShort Nasdaq Biotech has a 12-month low of $17.52 and a 12-month high of $29.66.
ILLEGAL ACTIVITY NOTICE: “ProShares UltraShort Nasdaq Biotech (BIS) Given Coverage Optimism Score of 0.07” was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://dakotafinancialnews.com/2018/04/13/proshares-ultrashort-nasdaq-biotech-bis-given-coverage-optimism-score-of-0-07.html.
About ProShares UltraShort Nasdaq Biotech
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
Receive News & Ratings for ProShares UltraShort Nasdaq Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotech and related companies with MarketBeat.com's FREE daily email newsletter.